AstraZeneca
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-09-27
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1100
- Registration Number
- NCT00226330
- Locations
- π¬π§
Research Site, Wiltshire, United Kingdom
A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)
- Conditions
- Hypercholesteremia
- First Posted Date
- 2005-09-26
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 840
- Registration Number
- NCT00225589
- Locations
- π³π΄
Research Site, Skedsmokorset, Norway
GALLANT 6 Tesaglitazar vs. Pioglitazone
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1450
- Registration Number
- NCT00214565
- Locations
- π¦π·
Research Sites, Quilmes - Buenos Aires, Argentina
π¬π§Research Site, Wiltshire, United Kingdom
π¬π§Research SIte, Reading, United Kingdom
LUNAR IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes
- Conditions
- Acute Coronary Syndromes
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 825
- Registration Number
- NCT00214630
- Locations
- π΅π¦
Research Site, Panama City, Panama
Type III Dysbetalipoproteinemia
- Conditions
- Hyperlipoproteinemia Type III
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00214604
- Locations
- πΏπ¦
Research Site, Cape Town, South Africa
GALLANT 5 Tesaglitazar Versus Metformin
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 580
- Registration Number
- NCT00214591
- Locations
- π¬π§
Research Sites, Northampton, United Kingdom
πΊπΈResearch Center, Sherwood, Arizona, United States
π¬π§Research Site, Wiltshire, United Kingdom
Seroquel on Glucose Metabolism
- Conditions
- Schizophrenia
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 572
- Registration Number
- NCT00214578
- Locations
- π¬π§
Research Site, Birmingham, United Kingdom
A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.
- Conditions
- GERD Without Erosive Esophagitis
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1400
- Registration Number
- NCT00206284
- Locations
- π¬π§
Research Site, Woking, United Kingdom
Crestor Versus Placebo in Subjects With Heart Failure
- Conditions
- Heart Failure
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5013
- Registration Number
- NCT00206310
- Locations
- π¬π§
Research Site, York, United Kingdom
Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 477
- Registration Number
- NCT00206219
- Locations
- π¬π§
Research Site, London, United Kingdom